Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals (Nasdaq: PHAT) has announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Phathom Pharmaceuticals (Nasdaq: PHAT) has announced its participation in two upcoming investor conferences. The first is the 22nd Annual Needham Virtual Healthcare Conference, where a fireside chat is scheduled for April 18, 2023, at 8:45 a.m. EDT, with one-on-one meetings throughout the conference from April 17-20, 2023. The second event is the H.C. Wainwright BioConnect Investor Conference in New York City, featuring a fireside chat on May 2, 2023, at 2:30 p.m. EDT. Investors can access live webcasts and archived recordings of these chats via the company’s website for 90 days post-event. Phathom focuses on novel treatments for gastrointestinal diseases, with exclusive rights to vonoprazan, a potassium-competitive acid blocker.
Details
News Market Reaction – PHAT
The recorded move for PHAT in the trading session of this news was +6.32%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the following upcoming investor conferences:
- 22nd Annual Needham Virtual Healthcare Conference, including a scheduled fireside chat on Tuesday, April 18, 2023 at 8:45 a.m. EDT. Management will also participate in one-on-one meetings throughout the conference, which runs from April 17-20, 2023.
- H.C. Wainwright BioConnect Investor Conference at NASDAQ in New York City. Management will participate in a fireside chat on Tuesday, May 2, 2023 at 2:30 p.m. EDT and one-on-one meetings throughout the day.
To access the live webcast and archived recordings of the fireside chats, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. The recordings will be available for 90 days following each event.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and Twitter.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2023 Phathom Pharmaceuticals. All rights reserved.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.